RxDoctor Payments Data

Mark O'Connor, MD

Cardiovascular Disease · Leominster, MANPI 1215297270

Payments from drug & device makers

$1,120in general payments, 2019–2025

Across 57 payments — averaging $19.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$312
  • Pfizer$265
  • Amgen$208
  • Johnson & Johnson$97
  • Boehringer Ingelheim$95
  • Sanofi-aventis U.S. LLC$49
  • plus $93 from 4 others

What the payments were for

  • Food & beverage$1,120100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,120 in reported general payments places this provider in the 45th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$228,839
Medicare patients
807
Services billed
3,039

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban689$801,150
XareltoRivaroxaban144$157,680
EntrestoSacubitril/Valsartan65$75,119
JardianceEmpagliflozin57$51,531
FarxigaDapagliflozin Propanediol25$38,654
Repatha SureclickEvolocumab31$31,877
Metoprolol Succinate788$15,571
Rosuvastatin Calcium401$15,092
Praluent PenAlirocumab24$13,407
BrilintaTicagrelor11$13,124
Atorvastatin Calcium469$9,223
Ezetimibe134$6,504
Ranolazine ErRanolazine29$4,219
Isosorbide Mononitrate ErIsosorbide Mononitrate176$3,804
Diltiazem 24hr Er (Cd)Diltiazem Hcl74$3,016

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$265$801,150689 claims
Johnson & JohnsonXarelto$97$157,680144 claims
NovartisEntresto$34$75,11965 claims
AstraZenecaFarxiga, Brilinta$16$51,77836 claims
Boehringer IngelheimJardiance$95$51,53157 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Leominster

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →